We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Stock Moves -1.66%: What You Should Know
Read MoreHide Full Article
CVS Health (CVS - Free Report) closed at $70.69 in the latest trading session, marking a -1.66% move from the prior day. This move was narrower than the S&P 500's daily loss of 2.08%. Meanwhile, the Dow lost 2.11%, and the Nasdaq, a tech-heavy index, lost 2.27%.
Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had lost 9.97% over the past month. This has lagged the Retail-Wholesale sector's loss of 4.18% and the S&P 500's loss of 3.6% in that time.
Investors will be hoping for strength from CVS as it approaches its next earnings release, which is expected to be February 14, 2019. On that day, CVS is projected to report earnings of $2.12 per share, which would represent year-over-year growth of 10.42%. Our most recent consensus estimate is calling for quarterly revenue of $50.40 billion, up 4.16% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $7.02 per share and revenue of $189.58 billion. These totals would mark changes of +18.98% and +2.61%, respectively, from last year.
Any recent changes to analyst estimates for CVS should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.19% lower. CVS is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that CVS has a Forward P/E ratio of 10.24 right now. This represents a discount compared to its industry's average Forward P/E of 12.06.
Investors should also note that CVS has a PEG ratio of 0.94 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Retail - Pharmacies and Drug Stores was holding an average PEG ratio of 1.17 at yesterday's closing price.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CVS in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Stock Moves -1.66%: What You Should Know
CVS Health (CVS - Free Report) closed at $70.69 in the latest trading session, marking a -1.66% move from the prior day. This move was narrower than the S&P 500's daily loss of 2.08%. Meanwhile, the Dow lost 2.11%, and the Nasdaq, a tech-heavy index, lost 2.27%.
Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had lost 9.97% over the past month. This has lagged the Retail-Wholesale sector's loss of 4.18% and the S&P 500's loss of 3.6% in that time.
Investors will be hoping for strength from CVS as it approaches its next earnings release, which is expected to be February 14, 2019. On that day, CVS is projected to report earnings of $2.12 per share, which would represent year-over-year growth of 10.42%. Our most recent consensus estimate is calling for quarterly revenue of $50.40 billion, up 4.16% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $7.02 per share and revenue of $189.58 billion. These totals would mark changes of +18.98% and +2.61%, respectively, from last year.
Any recent changes to analyst estimates for CVS should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.19% lower. CVS is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that CVS has a Forward P/E ratio of 10.24 right now. This represents a discount compared to its industry's average Forward P/E of 12.06.
Investors should also note that CVS has a PEG ratio of 0.94 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Retail - Pharmacies and Drug Stores was holding an average PEG ratio of 1.17 at yesterday's closing price.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CVS in the coming trading sessions, be sure to utilize Zacks.com.